NexImmune elects to launch initial public offering
Amgen and Pfizer-backed oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.
Volta plugs into $125m series D
Invenergy unit Energize Ventures returned for a series D round that lifted the electric vehicle charger provider's total equity funding to $200m.
Bolt Biotherapeutics charges to IPO stage
Novo and Pfizer are among the investors set to exit the cancer therapy developer, which has set a $100m target for its initial public offering.
Aledade aligns with corporates to raise $100m
GV-backed Aledade has secured series D funding at a $2.2bn post-money valuation to build out the business model for its primary care network.
Wattpad navigates to Naver in $600m acquisition
Bennett Coleman & Co, Globe Telecom and Tencent are set to exit the story sharing community operator in a cash-and-stock acquisition transaction by Naver.
Terns tracks $100m in IPO
Lilly Asia Ventures is the largest shareholder of liver disease therapy developer Terns, which closed a $97.7m round earlier this month.
Quali counts up $54m
The Dell and Orr Partners-backed cloud software developer has collected $54m in a round co-led by Greenfield Partners and Jerusalem Venture Partners.
Groove X tunes into $26m series B3 round
Hitachi Global Life Solutions, Sompo and NTT Docomo provided the cash for the creator of a family companion robot called Lovot, taking its total funding to $128m.

News Continued

Rivian trucks in $2.65bn
Amazon returned for a round valuing the electric truck developer at $27.6bn as it prepares to release its first vehicles later this year.
PPRO progresses with $180m
The PayPal and Citi-backed cross-border payment technology provider has raised new funding at a valuation topping $1bn.
Globality gulps down $138m in series E
SoftBank Vision Fund returned to reinvest in the outsourcing marketplace operator at a valuation of almost $1bn to take its total funding to $310m.
Vor Biopharma goes for $150m in IPO
PureTech Health, Johnson & Johnson and Novartis are in line for exits after the cancer drug developer filed for its initial public offering.
Immunocore plots course to $100m IPO
The immunotherapy developer plans to go public in the United States having raised $565m from investors including Eli Lilly and WuXi AppTec.
Sensei looks to master public markets
Cambrian Biopharma is the largest investor in cancer immunotherapy developer Sensei Biotherapeutics, which has filed to raise up to $100m.

Editor's Picks

Rivian trucks in $2.65bn
Amazon returned for a round valuing the electric truck developer at $27.6bn as it prepares to release its first vehicles later this year.
Visa releases Plaid from acquisition agreement
The $5.3bn purchase agreed a year ago would have enabled Alphabet, Mastercard, Citi and American Express to exit the banking software producer.
Proterra opts for reverse merger route
Mitsui, Edison Energy, BMW, Daimler, General Motors and Exelon-backed electric bus manufacturer Proterra achieved a $1.6bn enterprise value in the deal.
SoFi's valuation soars in reverse merger deal
SoftBank and Renren-backed online financial services provider SoFi will list on the New York Stock Exchange at an $8.65bn valuation double that of its last round.
test reg